IL307269A - Ert2 mutants and uses thereof - Google Patents

Ert2 mutants and uses thereof

Info

Publication number
IL307269A
IL307269A IL307269A IL30726923A IL307269A IL 307269 A IL307269 A IL 307269A IL 307269 A IL307269 A IL 307269A IL 30726923 A IL30726923 A IL 30726923A IL 307269 A IL307269 A IL 307269A
Authority
IL
Israel
Prior art keywords
ert2
mutations
ert2 mutations
Prior art date
Application number
IL307269A
Other languages
English (en)
Hebrew (he)
Original Assignee
Senti Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senti Biosciences Inc filed Critical Senti Biosciences Inc
Publication of IL307269A publication Critical patent/IL307269A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL307269A 2021-04-06 2022-04-06 Ert2 mutants and uses thereof IL307269A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171227P 2021-04-06 2021-04-06
PCT/US2022/023673 WO2022216823A1 (en) 2021-04-06 2022-04-06 Ert2 mutants and uses thereof

Publications (1)

Publication Number Publication Date
IL307269A true IL307269A (en) 2023-11-01

Family

ID=83546546

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307269A IL307269A (en) 2021-04-06 2022-04-06 Ert2 mutants and uses thereof

Country Status (9)

Country Link
US (1) US20240150433A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320228A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513231A (cg-RX-API-DMAC7.html)
KR (1) KR20240004433A (cg-RX-API-DMAC7.html)
CN (1) CN117321192A (cg-RX-API-DMAC7.html)
AU (1) AU2022255180A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213591A1 (cg-RX-API-DMAC7.html)
IL (1) IL307269A (cg-RX-API-DMAC7.html)
WO (1) WO2022216823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024163908A2 (en) * 2023-02-02 2024-08-08 Senti Biosciences, Inc. Improved ert2 mutants, inducible cell death systems, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097050A2 (en) * 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
CA2485939C (en) * 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US20070087346A1 (en) * 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
WO2014172470A2 (en) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
EP3585394A4 (en) * 2017-02-23 2021-06-30 Olema Pharmaceuticals, Inc. COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY
KR102109820B1 (ko) * 2018-04-16 2020-05-12 한양대학교 산학협력단 비스페놀 a와의 결합력이 향상된 돌연변이 에스트로겐 수용체 단백질 및 이를 이용한 박테리아 균주

Also Published As

Publication number Publication date
CN117321192A (zh) 2023-12-29
CA3213591A1 (en) 2022-10-13
EP4320228A4 (en) 2025-07-02
AU2022255180A1 (en) 2023-11-16
KR20240004433A (ko) 2024-01-11
JP2024513231A (ja) 2024-03-22
EP4320228A1 (en) 2024-02-14
WO2022216823A1 (en) 2022-10-13
US20240150433A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
IL286969A (en) Stat degraders and uses thereof
IL281568A (en) Collagen-localized immunomodulatory molecules and methods thereof
EP4262883C0 (en) PEG LIPIDS AND LIPID NANOPARTICLES
IL272137A (en) Interleukin-21 muteins and methods of treatment
HUE065882T2 (hu) Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
EP3939266A4 (en) LIMITED AND ADAPTED APPLICATIONS OF COMBINED INTER AND INTRA PREDICTION MODES
EP3544618A4 (en) MODIFIED CELL EXPANSION AND USES THEREOF
DK3990028T3 (da) Micellære nanopartikler og anvendelse deraf
EP3959307A4 (en) Engineered cells and uses thereof
EP4468534A4 (en) CONNECTOR SHEET AND CONNECTOR
IL312330A (en) Tyk2 degraders and uses thereof
EP4294790A4 (en) SMARCA DEGRADING AGENTS AND RELATED USES
EP4342532C0 (en) Antiplatelet drugs and their uses
EP4182351A4 (en) CD19-BINDING MOLECULES AND THEIR USES
EP4329739A4 (en) LIPID NANOMATERIALS AND THEIR USES
EP4301784A4 (en) Antibodies against claudin-6 and uses thereof
EP4504190A4 (en) OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES
IL310931A (en) 6-aza-quinoline derivatives and related uses
EP3856755A4 (en) Terpinoid derivatives and uses thereof
EP4350263A4 (en) WASHING/DRYING APPARATUS AND WASHING/DRYING METHOD
EP4444744A4 (en) ARRDC1-Mediated Microvesicle Degradation System (ARMM) and its Uses
EP4106813A4 (en) CD137 BINDING MOLECULES AND THEIR USES
EP4198040C0 (de) Pt-dpephos-iod-komplex und pt-dpephos-brom-komplex
EP4263615A4 (en) Gucy2c binding molecules and uses thereof
EP4263612A4 (en) Mesothelin binding molecules and uses thereof